Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1595097 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $9.09Day +0.06%Mkt cap $168M1Y −5.3%Off 52W high −55.8%Vol (1Y) 79.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,941 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.3% of sh out |
| Days to cover5.9d |
| 13F net flow (QoQ)+2.21% |
| Top-10 13F concentration70.9% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$84.5M |
| ROE−54.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+11.6% |
| 1Y−5.3% |
| 3Y+37.7% |
| 5Y−79.7% |
| 10Y−89.5% |
| Since incept. (ann.)−17.9% |
Total return through 2026-07-28 · series begins 2014-11-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)79.8% |
| Ann. volatility (3Y)174.7% |
| Sharpe (1Y)0.35 |
| Sharpe (3Y)0.61 |
| Max drawdown (1Y)−61.9% |
| Max drawdown (3Y)−92.0% |
| Beta (3Y vs SPY)1.63 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 2.3M | $22M | 12.66% | +0.0% |
| ORBIMED ADVISORS LLC | 1.7M | $16M | 9.38% | +8.8% |
| Aberdeen Group plc | 1.3M | $12M | 7.13% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 734,106 | $7M | 3.96% | new |
| CITADEL ADVISORS LLC | 727,060 | $7M | 3.92% | −13.8% |
| Prosight Management, LP | 697,108 | $7M | 3.76% | +1.9% |
| DIADEMA PARTNERS LP | 439,957 | $4M | 2.37% | new |
| Stonepine Capital Management, LLC | 383,462 | $4M | 2.07% | −1.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$1.23 | — | — | — |
| 2025-09-30 | 2025-11-12 | −$1.90 | — | — | — |
| 2025-06-30 | 2025-08-05 | −$1.44 | — | — | — |
| 2025-03-31 | 2025-05-06 | −$1.39 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
